tiprankstipranks
Advertisement
Advertisement

TBPH Stock Latest News

Theravance Biopharma details Phase 3 ampreloxetine data
Company AnnouncementsTheravance Biopharma details Phase 3 ampreloxetine data
10d ago
8K
TBPH
Theravance Biopharma reports Q2 revenue $20.7M, consensus $22.32M
PremiumThe Fly
Theravance Biopharma reports Q2 revenue $20.7M, consensus $22.32M
26d ago
TBPH
TBPH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
TBPH Earnings Report this Week: Is It a Buy, Ahead of Earnings?
1M ago
TBPH
Theravance Biopharma downgraded to Neutral from Buy at H.C. Wainwright
PremiumThe Fly
Theravance Biopharma downgraded to Neutral from Buy at H.C. Wainwright
2M ago
TBPH
Zymeworks price target raised to $37 from $35 at Citi
PremiumThe Fly
Zymeworks price target raised to $37 from $35 at Citi
2M ago
TBPH
ZYME
Theravance Biopharma downgraded to Neutral from Buy at BTIG
PremiumThe FlyTheravance Biopharma downgraded to Neutral from Buy at BTIG
2M ago
TBPH
Morning Movers: Comcast surges after announcing spinoff of NBCUniversal
Premium
The Fly
Morning Movers: Comcast surges after announcing spinoff of NBCUniversal
2M ago
VZ
BTI
Theravance Biopharma downgraded to Hold from Buy at JonesResearch
Premium
The Fly
Theravance Biopharma downgraded to Hold from Buy at JonesResearch
2M ago
TBPH
Theravance Biopharma to be Acquired by Zymeworks
PremiumCompany Announcements
Theravance Biopharma to be Acquired by Zymeworks
2M ago
8K
TBPH
M&A News: Biotech Group Zymeworks Buys Lung Disease-Fighting Peer Theravance for $1B
PremiumMarket News
M&A News: Biotech Group Zymeworks Buys Lung Disease-Fighting Peer Theravance for $1B
2M ago
TBPH
ZYME
Theravance Biopharma to be acquired by Zymeworks for $17.00 per share in cash
PremiumThe Fly
Theravance Biopharma to be acquired by Zymeworks for $17.00 per share in cash
2M ago
TBPH
ZYME
Zymeworks to acquire Theravance Biopharma for $17.00 per share, or $929M
PremiumThe Fly
Zymeworks to acquire Theravance Biopharma for $17.00 per share, or $929M
2M ago
TBPH
ZYME
Zymeworks to acquire Theravance Biopharma for $17.00 per share
PremiumThe FlyZymeworks to acquire Theravance Biopharma for $17.00 per share
2M ago
TBPH
ZYME
Theravance Biopharma announces leadership changes amid restructuring
Premium
Company Announcements
Theravance Biopharma announces leadership changes amid restructuring
2M ago
8K
TBPH
Theravance Biopharma Shareholders Back Directors and Governance Plans
Premium
Company Announcements
Theravance Biopharma Shareholders Back Directors and Governance Plans
3M ago
8K
TBPH
Theravance Biopharma: Solid 1Q26 Execution, Cost Cuts, and YUPELRI Momentum Drive Buy Rating and Price Target Increase to $19
PremiumRatings
Theravance Biopharma: Solid 1Q26 Execution, Cost Cuts, and YUPELRI Momentum Drive Buy Rating and Price Target Increase to $19
3M ago
TBPH
Theravance: Hold Rating Reiterated as Restructuring Progress and Cash Flow Visibility Support Unchanged $15 Price Target
PremiumRatings
Theravance: Hold Rating Reiterated as Restructuring Progress and Cash Flow Visibility Support Unchanged $15 Price Target
4M ago
TBPH
Theravance Biopharma reports Q1 EPS (10c) vs. (17c) last year
PremiumThe Fly
Theravance Biopharma reports Q1 EPS (10c) vs. (17c) last year
4M ago
TBPH
TBPH Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
TBPH Upcoming Earnings Report: What to Expect?
4M ago
TBPH
Theravance Biopharma price target raised to $17 from $14 at B. Riley
PremiumThe FlyTheravance Biopharma price target raised to $17 from $14 at B. Riley
5M ago
MNKD
TBPH
Theravance Secures Long-Term YUPELRI Patent Litigation Settlement
Premium
Company Announcements
Theravance Secures Long-Term YUPELRI Patent Litigation Settlement
5M ago
8K
TBPH
Theravance Biopharma price target raised to $15 from $13 at TD Cowen
Premium
The Fly
Theravance Biopharma price target raised to $15 from $13 at TD Cowen
6M ago
TBPH

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >